JP2017502957A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502957A5 JP2017502957A5 JP2016543097A JP2016543097A JP2017502957A5 JP 2017502957 A5 JP2017502957 A5 JP 2017502957A5 JP 2016543097 A JP2016543097 A JP 2016543097A JP 2016543097 A JP2016543097 A JP 2016543097A JP 2017502957 A5 JP2017502957 A5 JP 2017502957A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- alkyl
- substituents selected
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 229940122357 Monoacylglycerol lipase inhibitor Drugs 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims 85
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 79
- 125000005843 halogen group Chemical group 0.000 claims 79
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 42
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 36
- -1 pyrrolidinylcarbonyl group Chemical group 0.000 claims 26
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 20
- 125000004043 oxo group Chemical group O=* 0.000 claims 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 16
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 14
- 125000004076 pyridyl group Chemical group 0.000 claims 14
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 125000003277 amino group Chemical group 0.000 claims 10
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 8
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 7
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 6
- 125000004193 piperazinyl group Chemical group 0.000 claims 6
- HNJBEVLQSNELDL-YZRHJBSPSA-N pyrrolidin-2-one Chemical group O=C1CC[14CH2]N1 HNJBEVLQSNELDL-YZRHJBSPSA-N 0.000 claims 6
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 5
- 125000001041 indolyl group Chemical group 0.000 claims 5
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims 4
- 125000005974 C6-C14 arylcarbonyl group Chemical group 0.000 claims 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 4
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000003367 polycyclic group Chemical group 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 3
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 3
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000005945 imidazopyridyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000005116 aryl carbamoyl group Chemical group 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000005554 pyridyloxy group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- KRTLYJDCOZBDAH-OAQYLSRUSA-N (4R)-1-[3-fluoro-5-(2-methylpyridin-3-yl)phenyl]-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-one Chemical compound FC=1C=C(C=C(C1)C=1C(=NC=CC1)C)N1C(C[C@H](C1)N1CCN(CC1)C1=NC=CC=N1)=O KRTLYJDCOZBDAH-OAQYLSRUSA-N 0.000 claims 1
- ACWGPXVJPMRMHD-JOCHJYFZSA-N (4R)-4-[4-(1,3-thiazole-4-carbonyl)piperazin-1-yl]-1-[1-[4-(trifluoromethyl)phenyl]indol-5-yl]pyrrolidin-2-one Chemical compound S1C=NC(=C1)C(=O)N1CCN(CC1)[C@@H]1CC(N(C1)C=1C=C2C=CN(C2=CC1)C1=CC=C(C=C1)C(F)(F)F)=O ACWGPXVJPMRMHD-JOCHJYFZSA-N 0.000 claims 1
- GHGYBXQHRZLJLK-LJQANCHMSA-N (4r)-4-[4-(1,3-thiazole-2-carbonyl)piperazin-1-yl]-1-[1-[5-(trifluoromethyl)pyrimidin-2-yl]indol-5-yl]pyrrolidin-2-one Chemical compound N1=CC(C(F)(F)F)=CN=C1N1C2=CC=C(N3C(C[C@H](C3)N3CCN(CC3)C(=O)C=3SC=CN=3)=O)C=C2C=C1 GHGYBXQHRZLJLK-LJQANCHMSA-N 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims 1
- 150000004885 piperazines Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 description 8
- 230000004770 neurodegeneration Effects 0.000 description 5
- 102100029814 Monoglyceride lipase Human genes 0.000 description 4
- 101710116393 Monoglyceride lipase Proteins 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000016273 neuron death Effects 0.000 description 4
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 3
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 3
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 3
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000025698 brain inflammatory disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000001259 mesencephalon Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- PKBXKBJNBFXIAB-UHFFFAOYSA-N 1-methyl-4-phenyl-3,6-dihydro-2H-pyridine Chemical compound CN1CCC(=CC1)c1ccccc1.CN1CCC(=CC1)c1ccccc1 PKBXKBJNBFXIAB-UHFFFAOYSA-N 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013269244 | 2013-12-26 | ||
| JP2013269244 | 2013-12-26 | ||
| PCT/JP2014/084752 WO2015099196A1 (en) | 2013-12-26 | 2014-12-25 | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502957A JP2017502957A (ja) | 2017-01-26 |
| JP2017502957A5 true JP2017502957A5 (enExample) | 2017-12-07 |
| JP6454349B2 JP6454349B2 (ja) | 2019-01-16 |
Family
ID=52434920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016543097A Active JP6454349B2 (ja) | 2013-12-26 | 2014-12-25 | モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤としての４−（ピペラジン−１−イル）−ピロリジン−２−オン化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9624170B2 (enExample) |
| EP (1) | EP3087067B1 (enExample) |
| JP (1) | JP6454349B2 (enExample) |
| WO (1) | WO2015099196A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2951521A1 (en) * | 2014-06-09 | 2015-12-17 | Takeda Pharmaceutical Company Limited | Radiolabeled compounds |
| EP3268360B1 (en) | 2015-03-09 | 2019-04-24 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| US10106556B2 (en) | 2015-03-30 | 2018-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10975081B2 (en) | 2015-07-23 | 2021-04-13 | Glaxosmithkline Intellectual Property Development Limited | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors |
| US10787423B2 (en) | 2015-09-14 | 2020-09-29 | The National Institute For Biotechnolgy In The Negev Ltd. | Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction |
| WO2017046794A1 (en) * | 2015-09-14 | 2017-03-23 | The National Institute for Biotechnology in the Negev Ltd. | Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting vdac oligomerization, apoptosis and mitochondria dysfunction |
| US10434099B2 (en) | 2016-09-22 | 2019-10-08 | The National Institute for Biotechnology in the Negev Ltd. | Methods for treating central nervous system disorders using VDAC inhibitors |
| MX2018004256A (es) * | 2015-10-14 | 2018-05-16 | Squibb Bristol Myers Co | Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. |
| JP6832342B2 (ja) | 2016-03-31 | 2021-02-24 | 武田薬品工業株式会社 | 複素環化合物 |
| PL3436444T3 (pl) * | 2016-03-31 | 2020-10-19 | Takeda Pharmaceutical Company Limited | Związek heterocykliczny |
| KR102643778B1 (ko) * | 2017-05-23 | 2024-03-05 | 하. 룬드벡 아크티에셀스카브 | 피라졸 magl 저해제 |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| CN107397955A (zh) * | 2017-08-23 | 2017-11-28 | 上海黛妆国际贸易有限公司 | 黑色素基因抑制剂 |
| EP3689879B1 (en) | 2017-09-29 | 2025-02-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EA202091429A1 (ru) * | 2017-12-18 | 2020-10-27 | Грюненталь Гмбх | Замещенные амиды i пирролидина |
| TW201927769A (zh) * | 2017-12-18 | 2019-07-16 | 德商歌林達有限公司 | 經取代之吡咯啶醯胺ｉｉ |
| CN112135825A (zh) | 2018-03-13 | 2020-12-25 | 夏尔人类遗传性治疗公司 | 血浆激肽释放酶抑制剂及其用途 |
| RS65727B1 (sr) * | 2018-06-27 | 2024-08-30 | Ptc Therapeutics Inc | Heterociklična i heteroaril jedinjenja za lečenje hantingtonove bolesti |
| JP2022503932A (ja) * | 2018-09-27 | 2022-01-12 | フォチョン・ファーマシューティカルズ・リミテッド | Ｒｅｔキナーゼ阻害剤としての置換イミダゾ［１，２－ａ］ピリジン及び［１，２，４］トリアゾロ［１，５－ａ］ピリジン化合物 |
| PE20211733A1 (es) | 2019-01-11 | 2021-09-06 | Gruenenthal Chemie | Amidas de pirrolidina sustituidas |
| DK4031547T3 (da) | 2019-09-18 | 2024-09-09 | Takeda Pharmaceuticals Co | Plasmakallikreininhibitorer og anvendelser deraf |
| CN114667289B (zh) | 2019-09-18 | 2025-08-26 | 武田药品工业有限公司 | 杂芳基血浆激肽释放酶抑制剂 |
| US20230140808A1 (en) | 2020-04-07 | 2023-05-04 | Sanofi | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer |
| EP3892614A1 (en) | 2020-04-07 | 2021-10-13 | Sanofi | (1h-indol-5-yl)acrylamide derivatives as inhibitors of tead proteins and the hippo-yap1/taz signaling cascade for the treatment of cancer |
| US20240382482A1 (en) * | 2021-03-17 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors |
| PE20240070A1 (es) * | 2021-05-06 | 2024-01-11 | Exscientia Ai Ltd | MODULADORES DE PKC-theta |
| JP2024536718A (ja) * | 2021-09-03 | 2024-10-08 | エフ． ホフマン－ラ ロシュ アーゲー | Ｍａｇｌ阻害剤 |
| CN118574807A (zh) | 2021-12-29 | 2024-08-30 | Psy治疗公司 | 抑制单酰基甘油脂肪酶（magl） |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445792A1 (de) | 1964-12-18 | 1969-01-02 | Bayer Ag | Verfahren zur Herstellung von Iminopyrrolidonen |
| BRPI0514077A (pt) * | 2004-08-02 | 2008-05-27 | Hoffmann La Roche | derivados de benzilóxi como inibidores de maob |
| JP2009275020A (ja) * | 2008-05-16 | 2009-11-26 | Institute Of Physical & Chemical Research | 細胞増殖阻害剤 |
| AR076380A1 (es) | 2009-04-22 | 2011-06-08 | Janssen Pharmaceutica Nv | Azetidinil diamidas inhibidoras de monoacilglicerol lipasa(mgl), composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades y patologias que incluyen dolor inflamatorio. |
| CN102458407B (zh) | 2009-04-22 | 2014-03-05 | 詹森药业有限公司 | 用作单酰甘油脂肪酶抑制剂的杂芳族和芳族哌嗪基氮杂环丁基酰胺 |
| TWI495637B (zh) | 2009-04-22 | 2015-08-11 | Janssen Pharmaceutica Nv | 用作單醯基甘油脂肪酶抑制劑之雜芳族及芳族六氫吡基吖丁啶基醯胺（一） |
| WO2011041713A2 (en) * | 2009-10-02 | 2011-04-07 | Glaxosmithkline Llc | Piperazinyl antiviral agents |
| WO2011050284A1 (en) * | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Pyrazolylpyridine antiviral agents |
| RU2013114771A (ru) | 2010-09-03 | 2014-10-10 | Янссен Фармацевтика Нв | Диамиды азетидинила как ингибиторы моноацилглицерол липазы |
| CA2810077A1 (en) | 2010-09-27 | 2012-04-05 | Peter J. Connolly | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors |
| CA2815350A1 (en) | 2010-10-22 | 2012-04-26 | Janssen Pharmaceutica Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| CN103841973A (zh) | 2011-09-30 | 2014-06-04 | 詹森药业有限公司 | 用于治疗代谢疾病和相关失调的单酰甘油脂肪酶抑制剂 |
| JP2014528428A (ja) * | 2011-09-30 | 2014-10-27 | ヤンセン ファーマシューティカ エヌ．ベー． | 代謝症及び関連障害の治療のためのモノアシルグリセロールリパーゼ阻害剤 |
| CN104379578B (zh) * | 2012-03-19 | 2017-06-09 | 阿比德治疗公司 | 氨基甲酸酯化合物及其制备和使用方法 |
-
2014
- 2014-12-25 JP JP2016543097A patent/JP6454349B2/ja active Active
- 2014-12-25 WO PCT/JP2014/084752 patent/WO2015099196A1/en not_active Ceased
- 2014-12-25 EP EP14833295.0A patent/EP3087067B1/en active Active
- 2014-12-25 US US15/108,000 patent/US9624170B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502957A5 (enExample) | ||
| HRP20201171T1 (hr) | Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti | |
| JOP20200042A1 (ar) | مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها | |
| CN109963854A (zh) | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 | |
| CO2019007711A2 (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| IL281773A (en) | Ophthalmic composition for treatment of dry eye disease | |
| HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| EA202190802A3 (ru) | Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1 | |
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| EA201791239A8 (ru) | ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
| EA201890001A1 (ru) | Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk) | |
| JP2010534647A5 (enExample) | ||
| MX2016012687A (es) | Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central. | |
| EP3541790C0 (en) | 3-(2-(4-PHENYLPIPERAZIN-1-YL)ETHYL)-2-OXA-8-AZASPIRO[4.5]DECAN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS 5-HYDROXYTRYPTAMINE (5-HT7) RECEPTOR 7 MODULATORS FOR THE TREATMENT OF PE, INFLAMMATORY BOWEL DISEASE, CIRCADIAN RHYTHM DISORDER, OR DEPRESSION | |
| FI3546462T3 (fi) | Uusi oksoisokinoliinijohdannainen | |
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| EA033250B1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| GEAP202416013A (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| RU2017112989A (ru) | Соединения и способы | |
| CL2015003196A1 (es) | Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2. | |
| MX387775B (es) | Derivado de 2-acilaminotiazol o sal del mismo. | |
| RU2014144951A (ru) | Новое 1-замещенное производное индазола | |
| HUE067669T2 (hu) | 7-fenoxi-N-(3-azabiciklo[3.2.1]oktán-8-il)-6,7-dihidro-5H-pirrolo[1,2-b][1,2,4]triazol-2-amin származékok és rokon vegyületek, mint gamma-szekretáz modulátorok az Alzheimer-kór kezelésére |